Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2013
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068
Yibing Yan, Violeta Serra, Ludmila Prudkin, et al.
Cancer Cell
|
March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
Cancer Discovery
|
November 23, 2016
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura, Desamparados Roda, Susana Roselló, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2020
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz, Katherine A Guthrie, Van K Morris, et al.
NPJ Precision Oncology
|
June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
Marie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, et al.
British Journal of Cancer
|
September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
Elizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, et al.
JAMA
|
March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Robert Haddad, Jérôme Fayette, Maria Teixeira, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2013
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068
Yibing Yan, Violeta Serra, Ludmila Prudkin, et al.
Cancer Cell
|
March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
Cancer Discovery
|
November 23, 2016
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura, Desamparados Roda, Susana Roselló, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2020
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz, Katherine A Guthrie, Van K Morris, et al.
NPJ Precision Oncology
|
June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
Marie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, et al.
British Journal of Cancer
|
September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
Elizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, et al.
JAMA
|
March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Robert Haddad, Jérôme Fayette, Maria Teixeira, et al.
Page
of 9